These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The role of immunomodulatory medications in the treatment of COVID-19. Sattui SE; Crow MK; Navarro-Millán I Curr Opin Rheumatol; 2021 Sep; 33(5):431-445. PubMed ID: 34397605 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of a fourth dose of COVID-19 mRNA vaccine in patients with systemic autoimmune rheumatic diseases using disease-modifying antirheumatic drugs: an emulated target trial. Hanberg JS; Fu X; Wang X; Patel NJ; Kawano Y; Schiff A; Kowalski EN; Cook CE; Vanni KMM; Guzzo K; Qian G; Bade KJ; Saavedra A; Venkat R; Srivatsan S; Zhang Y; Sparks JA; Wallace ZS Lancet Rheumatol; 2024 Jan; 6(1):e21-e30. PubMed ID: 38258675 [TBL] [Abstract][Full Text] [Related]
4. Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe? Santos CS; Férnandez XC; Moriano Morales C; Álvarez ED; Álvarez Castro C; López Robles A; Pérez Sandoval T RMD Open; 2021 Jan; 7(1):. PubMed ID: 33455920 [TBL] [Abstract][Full Text] [Related]
5. The serological immunogenicity of the third and fourth doses of COVID-19 vaccine in patients with inflammatory rheumatic diseases on different biologic or targeted DMARDs: a Swedish nationwide study (COVID-19-REUMA). Frodlund M; Nived P; Chatzidionysiou K; Södergren A; Klingberg E; Hansson M; Ohlsson S; Pin E; Bengtsson A; Klareskog L; Kapetanovic M Microbiol Spectr; 2024 Apr; 12(4):e0298123. PubMed ID: 38441463 [TBL] [Abstract][Full Text] [Related]
10. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Gianfrancesco M; Hyrich KL; Al-Adely S; Carmona L; Danila MI; Gossec L; Izadi Z; Jacobsohn L; Katz P; Lawson-Tovey S; Mateus EF; Rush S; Schmajuk G; Simard J; Strangfeld A; Trupin L; Wysham KD; Bhana S; Costello W; Grainger R; Hausmann JS; Liew JW; Sirotich E; Sufka P; Wallace ZS; Yazdany J; Machado PM; Robinson PC; Ann Rheum Dis; 2020 Jul; 79(7):859-866. PubMed ID: 32471903 [TBL] [Abstract][Full Text] [Related]
11. Risk of COVID-19 infection in patients with rheumatic disease taking disease-modifying anti-rheumatic drugs. Yousefghahari B; Navari S; Sadeghi M; Soleimaniamiri S; Soleimaniamiri M; Heidari B; Babaei M; Ghodrati K; Guran A; Gholinia H Clin Rheumatol; 2021 Oct; 40(10):4309-4315. PubMed ID: 34052904 [TBL] [Abstract][Full Text] [Related]
12. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Tugwell P; Wells GA Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012437. PubMed ID: 27855242 [TBL] [Abstract][Full Text] [Related]
13. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Singh JA; Hossain A; Tanjong Ghogomu E; Kotb A; Christensen R; Mudano AS; Maxwell LJ; Shah NP; Tugwell P; Wells GA Cochrane Database Syst Rev; 2016 May; 2016(5):CD012183. PubMed ID: 27175934 [TBL] [Abstract][Full Text] [Related]
14. Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy. Spila Alegiani S; Crisafulli S; Giorgi Rossi P; Mancuso P; Salvarani C; Atzeni F; Gini R; Kirchmayer U; Belleudi V; Kurotschka PK; Leoni O; Ludergnani M; Ferroni E; Baracco S; Massari M; Trifirò G; Rheumatology (Oxford); 2021 Oct; 60(SI):SI25-SI36. PubMed ID: 33856453 [TBL] [Abstract][Full Text] [Related]
15. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Akiyama S; Hamdeh S; Micic D; Sakuraba A Ann Rheum Dis; 2021 Mar; 80(3):384-391. PubMed ID: 33051220 [TBL] [Abstract][Full Text] [Related]
16. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs. Michelena X; Borrell H; López-Corbeto M; López-Lasanta M; Moreno E; Pascual-Pastor M; Erra A; Serrat M; Espartal E; Antón S; Añez GA; Caparrós-Ruiz R; Pluma A; Trallero-Araguás E; Barceló-Bru M; Almirall M; De Agustín JJ; Lladós J; Julià A; Marsal S Semin Arthritis Rheum; 2020 Aug; 50(4):564-570. PubMed ID: 32425260 [TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of Covid-19 in patients with rheumatic diseases and the effects of the pandemic on rheumatology outpatient care: A single-centre experience from Turkey. Batıbay S; Koçak Ulucaköy R; Özdemir B; Günendi Z; Göğüş FN Int J Clin Pract; 2021 Sep; 75(9):e14442. PubMed ID: 34105856 [TBL] [Abstract][Full Text] [Related]
18. Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience. Migkos MP; Kaltsonoudis E; Pelechas E; Drossou V; Karagianni PG; Kavvadias A; Voulgari PV; Drosos AA Rheumatol Int; 2021 May; 41(5):903-909. PubMed ID: 33655421 [TBL] [Abstract][Full Text] [Related]
19. Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic. Favalli EG; Maioli G; Biggioggero M; Caporali R Expert Rev Clin Immunol; 2021 Jun; 17(6):561-571. PubMed ID: 33787418 [No Abstract] [Full Text] [Related]
20. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis. Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]